REG - Hikma Pharmaceutical - Director/PDMR Shareholding
RNS Number : 2641UHikma Pharmaceuticals Plc21 November 2019Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging managerial responsibilities
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mohammed 'Ali' Al-Husry
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083
b)
Nature of the transaction
Mr. Al-Husry has a beneficial interest in DKYB Limited, which holds shares in Hikma. DKYB Limited previously had 1,109,748 Hikma shares pledged to Citibank Switzerland. On 19 November 2019 the pledge arrangement was changed so that 989,748 shares were pledged to Citibank Jersey and 120,000 shares were pledged to Citibank Switzerland. Both Citibank Switzerland and Citibank Jersey are ultimately wholly owned by Citigroup Inc.
c)
Price(s) and volume(s)
Price(s): £0.00p
Volume(s): 0
d)
Aggregated information
Aggregated volume: 0
Price: £0.00p
e)
Date of the transaction
19 November 2019
f)
Place of the transaction
London
Peter Speirs, Company Secretary, Responsible for releasing this announcement
21 November 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHBSBDBLSDBGCB
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement